Boussard & Gavaudan Investment Management LLP acquired a new position in Solventum Co. (NYSE:SOLV - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 63,638 shares of the company's stock, valued at approximately $4,308,000.
A number of other institutional investors and hedge funds have also recently modified their holdings of SOLV. Price T Rowe Associates Inc. MD purchased a new position in shares of Solventum in the 1st quarter worth approximately $5,889,000. LRI Investments LLC acquired a new stake in Solventum in the 1st quarter worth approximately $43,000. EverSource Wealth Advisors LLC acquired a new stake in Solventum in the 1st quarter worth approximately $30,000. GAMMA Investing LLC acquired a new stake in Solventum in the 2nd quarter worth approximately $74,000. Finally, Massmutual Trust Co. FSB ADV acquired a new stake in Solventum in the 2nd quarter worth approximately $34,000.
Solventum Stock Performance
NYSE SOLV traded up $0.99 on Thursday, hitting $72.48. 702,921 shares of the company's stock traded hands, compared to its average volume of 1,695,591. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. The firm's 50-day moving average price is $70.51 and its two-hundred day moving average price is $62.47. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05.
Analysts Set New Price Targets
A number of analysts recently commented on SOLV shares. Stifel Nicolaus started coverage on shares of Solventum in a research note on Tuesday, October 8th. They issued a "buy" rating and a $82.00 target price for the company. Wells Fargo & Company lowered their target price on shares of Solventum from $69.00 to $64.00 and set an "equal weight" rating for the company in a research note on Friday, August 9th. Piper Sandler lifted their target price on shares of Solventum from $71.00 to $75.00 and gave the stock a "neutral" rating in a research note on Friday, November 8th. BTIG Research started coverage on shares of Solventum in a research note on Thursday, September 5th. They set a "neutral" rating for the company. Finally, The Goldman Sachs Group lifted their price objective on shares of Solventum from $48.00 to $54.00 and gave the company a "sell" rating in a research note on Monday, August 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average price target of $68.00.
Read Our Latest Report on Solventum
Solventum Company Profile
(
Free Report)
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Read More
Before you consider Solventum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Solventum wasn't on the list.
While Solventum currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
